Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Key Inclusion Criteria:

• Histologically confirmed diagnosis of SCLC.

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

• Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)as assessed by investigator per RECIST v1.1 criteria.

• Documentation of radiological disease progression after 1 prior line ofplatinum-containing chemotherapy (defined as at least 2 cycles of treatment) with orwithout therapy directed against programmed cell death protein 1 (PD-1) orprogrammed cell death ligand 1 (PD-L1; PD-1 and PD-L1 are hereafter referred to asPD-(L)1) for ES-SCLC.

Key Exclusion Criteria:

• Chemotherapy-free interval (CTFI) time from the last dose of first-lineplatinum-containing chemotherapy to the occurrence of progressive disease) < 30 days (independent of the immunotherapy maintenance).

• Received any prior treatment with irinotecan, topotecan, SG, SN-38, exatecanderivatives, and similar agents targeting topoisomerase I.

• Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.Participants with previously treated brain metastases may participate provided theyhave stable CNS disease (ie, without evidence of progression) for at least 4 weeksprior to enrollment and all neurologic symptoms have returned to baseline, have noevidence of new or enlarging brain metastases, and are taking ≤ 10 mg/day ofprednisone or its equivalent.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.